Skip to content

Study · Case report or series · n = 3 · 2018

4 results

MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.

Clément K, Biebermann H, Farooqi IS, Van der Ploeg L, Wolters B, Poitou C, Puder L, Fiedorek F, Gottesdiener K, Kleinau G, Heyder N, Scheerer P and 13 more

Show all authors

Blume-Peytavi U, Jahnke I, Sharma S, Mokrosinski J, Wiegand S, Müller A, Weiß K, Mai K, Spranger J, Grüters A, Blankenstein O, Krude H, Kühnen P

Nature medicine7 May 2018Cited by 251 (Europe PMC)

PMID29736023 (opens in a new tab)DOI10.1038/s41591-018-0015-9 (opens in a new tab)PepBankPUB-29736023
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In three severely obese LEPR-deficient individuals, setmelanotide produced substantial, durable reductions in hyperphagia over 45-61 weeks of observation.

    In plain wordsIn three severely obese LEPR-deficient individuals, hunger decreased during setmelanotide treatment over 45-61 weeks of observation.

    Peptide
    Setmelanotide
    Outcome
    DecreaseHyperphagia
    Study

    n = 3

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Three severely obese LEPR-deficient individuals were administered the MC4R agonist setmelanotide, resulting in substantial and durable reductions in hyperphagia and body weight over an observation period of 45-61 weeks.
  2. 02HumanCase report or seriesEfficacy outcome

    In three severely obese LEPR-deficient individuals, setmelanotide produced substantial, durable weight reductions over 45-61 weeks of observation.

    In plain wordsIn three severely obese LEPR-deficient individuals, weight decreased during setmelanotide treatment over 45-61 weeks of observation.

    Peptide
    Setmelanotide
    Outcome
    DecreaseBody weight
    Study

    n = 3

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Three severely obese LEPR-deficient individuals were administered the MC4R agonist setmelanotide, resulting in substantial and durable reductions in hyperphagia and body weight over an observation period of 45-61 weeks.
  3. 03LabIn vitro (cells)Mechanism

    For selected MC4R variants, setmelanotide uniquely activated NFAT signaling compared with formerly tested MC4R agonists.

    In plain wordsIn lab tests, setmelanotide uniquely activated NFAT signaling compared with formerly tested MC4R agonists.

    Peptide
    Setmelanotide
    Outcome
    IncreaseNFAT signaling activation
    Study

    n: not reported in source

    Selected MC4R variants
    Comparator
    Formerly developed and tested MC4R agonists
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to formerly developed and tested MC4R agonists, setmelanotide has the unique capability of activating nuclear factor of activated T cell (NFAT) signaling and restoring function of this signaling pathway for selected MC4R variants.
  4. 04LabIn vitro (cells)Mechanism

    For selected MC4R variants, setmelanotide uniquely restored NFAT signaling function compared with formerly tested MC4R agonists.

    In plain wordsIn lab tests, setmelanotide uniquely restored NFAT signaling for selected MC4R variants compared with formerly tested MC4R agonists.

    Peptide
    Setmelanotide
    Outcome
    IncreaseNFAT signaling restoration
    Study

    n: not reported in source

    Selected MC4R variants
    Comparator
    Formerly developed and tested MC4R agonists
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to formerly developed and tested MC4R agonists, setmelanotide has the unique capability of activating nuclear factor of activated T cell (NFAT) signaling and restoring function of this signaling pathway for selected MC4R variants.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.